Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis.

This is preclinical mechanistic work in rats and cultured cardiomyocytes, so its reported cardioprotective effect should not be extrapolated to humans. The mechanistic case is well-controlled, with March5 knockdown reversing the benefit and pointing to a specific ferroptosis pathway. Regard it as a promising early signal that motivates further study, not clinical evidence.